Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bioasis Technologies Inc. V.BTI

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factors and the xB3™ platform, a proprietary technology for the delivery of therapeutics across the blood brain barrier and the treatment of CNS disorders in areas of high unmet medical need. The in-house development programs are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders.


TSXV:BTI - Post by User

Post by chrispion Feb 22, 2022 9:28am
162 Views
Post# 34449677

just a few facts

just a few factsNothing going on?

I must correct Finallytherock with a few facts:
 
  • Bioasis doubled the # of employees in the company in the 2nd half of last year. All these positions were in the project management area. You don’t do this if you don’t have internal and partner projects to manage.
 
  • They hired Shadow Lake Group to help them identify opportunities with partners and better negotiate commercial terms with partners. SLG is well respected in the industry with a big rolodex.
 
  • They hired NY-headquartered investment bank Ladenburg Thalmann in December to assist the Board in evaluating strategic alternatives, including potential M&A. LT is a great firm (not the top shelf JP Morgan, Morgan Stanley, Goldman) but has an excellent reputation.
Was Bioasis approached with some type of “opportunity” and they brought in experts to help them navigate and see what other “offers” might be out there?
 
  • Companies like SLG and LT are not engaged with a micro-cap company for their monthly retainer fees. They are motivated based on performance bonuses.
 
  • It was announced at the AGM (Dec/2021) that Mario Saltarelli took the additional role of CMO (Chief Medical Officer) for Bioasis. A person with his credentials and experience probably gets asked three times a week to join a company’s board or other position. For him to want to devote more of his precious time to Bioasis activities is a huge endorsement of the future of the company. He would not have done it otherwise.
Remember also that in Nov/2021 Denali announced first human proof of concept for its delivery technology against a lysosomal storage disorder. Bioasis's delivery technology is quantitatively superior preclinically and should perform equal to or better than Denali's according to Dr. Mario Saltarelli.

<< Previous
Bullboard Posts
Next >>